ARKK Holdings of Beam Therapeutics (BEAM) - Updated Daily
TherapeuticsGene TherapyGenomicsGene Base Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 2.14% | $1.86b |
| 🏋🏿♂️Weight Rank In ARKK | 🌏Country |
| 19 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 20 | |
| 🎫ARK Ownership Percent | |
| 7.67% | |
| Description | |
|---|---|
| beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other | |
| Website | |
| beamtx.com |
Other ETFs That Hold BEAM
Research Notes and Commentary for BEAM
No Research Notes Found for BEAM